<DOC>
	<DOCNO>NCT00810277</DOCNO>
	<brief_summary>This single arm study assess safety efficacy tocilizumab patient moderate severe active rheumatoid arthritis inadequate response current non-biologic DMARDs . Patients receive iv infusion tocilizumab 8mg/kg every 4 week total 6 infusion , either monotherapy combination current non-biologic DMARDs .</brief_summary>
	<brief_title>A Study Tocilizumab Patients With Rheumatoid Arthritis Who Have Inadequate Response Current Non-Biologic DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; moderate severe rheumatoid arthritis ; inadequate response current nonbiologic DMARDs rheumatic autoimmune disease inflammatory joint disease rheumatoid arthritis ; previous treatment biologics .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>